Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

$110 million vaccine research centre to be built in Saskatoon

Amy Jo Ehman
CMAJ March 13, 2007 176 (6) 751; DOI: https://doi.org/10.1503/cmaj.070214
Amy Jo Ehman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2007 Canadian Medical Association or its licensors

An advanced vaccine research station, to be constructed in Saskatoon by 2010, will put Canada at the forefront of the worldwide fight against infectious diseases such as SARS, avian influenza, hepatitis C and tuberculosis.

The International Vaccine Center (InterVac) will be a Level-3 facility for developing and testing vaccines for both human and animal diseases. About 75% of emerging diseases, including West Nile virus and variant bovine spongiform encephalopathy, are linked to animals.

The $110 million facility at the University of Saskatchewan will have the capacity to conduct research on large animal populations, such as chickens, cattle and pigs.

“The scope of InterVac is unique, literally being able to work on hundreds of animals, and different species of animals, at the same time,” says Andrew Potter, associate director of research at the Vaccine Infectious Disease Organization (VIDO), a University of Saskatchewn facility that has been studying animal diseases nearly 30 years.

To boost Canada's response to emerging health threats, the federal government pledged $25 million in January for InterVac, topping up a $24 million allocation from the previous federal government in 2005.

“Scientists predict that a new disease will be discovered every 14 to 16 months and that understanding the animal– health interface will be key in developing vaccines,” says Alain Desroches of the Public Health Agency of Canada. Canada's capacity to prepare for emerging viruses will be “greatly increased” by InterVac.

One of the largest vaccine research labs in North America, InterVac will be situated within a cluster of life-science institutions, including the College of Medicine, the Western College of Veterinary Medicine, VIDO and the Synchrotron, which has 1 of only 3 biomedical imaging beamlines in the world.

“To have the veterinary school and the medical school close by is a wonderful advantage,” says Potter. “InterVac will be truly collaborative, not just on this campus, but on an international basis.”

He says the facility is expected to attract researchers from around the world, and will collaborate with the pharmaceutical industry for funding and to produce the vaccines.

The other major federally supported inititiave on vaccines is the Montréal-based Canadian Network for Vaccines and Immunotherapeutics, one of the Networks-of-Centres-of-Excellence.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 176 (6)
CMAJ
Vol. 176, Issue 6
13 Mar 2007
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
$110 million vaccine research centre to be built in Saskatoon
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
$110 million vaccine research centre to be built in Saskatoon
Amy Jo Ehman
CMAJ Mar 2007, 176 (6) 751; DOI: 10.1503/cmaj.070214

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
$110 million vaccine research centre to be built in Saskatoon
Amy Jo Ehman
CMAJ Mar 2007, 176 (6) 751; DOI: 10.1503/cmaj.070214
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • National survey highlights worsening primary care access
  • How Canadian hospitals are decreasing carbon emissions
Show more News

Similar Articles

Collections

  • Topics
    • Infectious diseases
    • Research methods & statistics

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire